Related Experiment Video

Updated: Jan 20, 2026

Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells
09:58

Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells

Published on: May 2, 2017

8.0K

Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients

Johanne Andersen Hojbjerg1, Eva Boysen Fynboe Ebert2, Michelle Simone Clement1

  • 1Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.

Lung Cancer (Amsterdam, Netherlands)
|August 27, 2019
PubMed
Abstract

Insights

Low plasma levels of miR-30b and miR-30c predict better outcomes for lung cancer patients with EGFR mutations treated with erlotinib. These microRNAs may serve as predictive biomarkers for non-small cell lung cancer (NSCLC) treatment response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC).
  • Tyrosine kinase inhibitors (TKIs) like erlotinib target EGFR, but resistance develops.
  • Specific microRNAs (miRNAs), including miR-30b, miR-30c, miR-221, and miR-222, are implicated in gefitinib resistance.

Purpose of the Study:

  • To investigate the predictive value of plasma miR-30b, miR-30c, miR-221, and miR-222.
  • To assess these miRNAs as potential biomarkers in EGFR-mutated NSCLC patients receiving erlotinib.

Main Methods:

  • Quantitative PCR (qPCR) analysis of plasma miRNA levels.
  • Correlation of pre-treatment plasma miRNA concentrations with clinical outcomes (PFS and OS).
  • Study cohort comprised 29 EGFR-mutated NSCLC patients on erlotinib therapy.

Main Results:

  • Low plasma concentrations of miR-30b and miR-30c significantly correlated with superior progression-free survival (PFS).
  • Low plasma miR-30c also significantly correlated with superior overall survival (OS).
  • High plasma levels of miR-30b and miR-30c predicted shorter PFS and OS.

Conclusions:

  • Plasma miR-30b and miR-30c levels show predictive potential for erlotinib treatment response in EGFR-mutated NSCLC.
  • These miRNAs may serve as valuable biomarkers for patient stratification and treatment guidance.
  • Further validation in larger cohorts is warranted to confirm clinical utility.
Keywords:
BiomarkersEGFR mutationsIntrinsic resistanceMicroRNANSCLC

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.0K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
43.5K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.7K
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries
45.4K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
62.5K